US ahead of Canada & Europe in Drug Approvals

A study has found that US FDA generally approves drugs faster and earlier than its counterparts in Canada and Europe.

A new study by Yale School of Medicine researchers has found that US FDA generally approves drugs faster and earlier than its counterparts in Canada and Europe. 

Regulatory review is the final step in the process of bringing new medicines from the lab to the patient and if the process is efficient, patients will get access to promising new therapies sooner, while ensuring drug safety.

'The perception that the FDA is too slow implies that sick patients are waiting unnecessarily for regulators to complete their review of new drug applications,’ said Nicholas Downing, a second-year medical student at Yale School of Medicine. He says he decided to conduct the research because there have been no recent comparisons of the FDA’s regulatory review